Bionomics Investor Presentation Deck
Compelling Rationale Supporting BNC210 in Ongoing ATTUNE Phase 2b PTSD Study 11
Reduced anxious behavior in many rodent
models AND reduced amygdala
hyperactivity in GAD patients
Therapeutic
Potential in PTSD
Underpinned by
Mechanism &
Pharmacology of
BNC210
FDA FAST TRACK D
A
Bionomics
FOR PTSD
REDUCES
ANXIETY
ANTI-
DEPRESSANT
ENHANCES
FEAR
EXTINCTION
ANTI-PANIC
ACTIVITY
REDUCES
THREAT
AVOIDANCE
Antidepressant effects in rat model AND in
PTSD trial at early time points
Enhanced fear extinction in mice AND
promoted more rapid recovery in healthy
humans following panic attack (CCK-4)
Reduced Number AND Intensity of Panic
Symptoms in Phase 1 CCK-4 challenge
Reduced threat avoidance behavior in
animals (various models of threat) AND in
GAD patients (Phase 2 study)View entire presentation